Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders

BACKGROUND: Clinical trials of immunotherapy have excluded patients with pre-existing autoimmune disease. While the safety and efficacy of single agent ipilimumab and anti-PD1 antibodies in patients with autoimmune disease has been examined in retrospective studies, no data are available for combina...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Lauren J, Weppler, Alison, Bhave, Prachi, Allayous, Clara, Patrinely Jr, J. Randall, Ott, Patrick, Sandhu, Shahneen, Haydon, Andrew, Lebbe, Celeste, Johnson, Douglas B, Long, Georgina V, Menzies, Alexander A, Carlino, Matteo S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108669/
https://www.ncbi.nlm.nih.gov/pubmed/33963010
http://dx.doi.org/10.1136/jitc-2020-002121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108669/
https://www.ncbi.nlm.nih.gov/pubmed/33963010
http://dx.doi.org/10.1136/jitc-2020-002121

Ejemplares similares